Live Breaking News & Updates on Microbiome Therapies

Stay updated with breaking news from Microbiome therapies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Microbiome-based treatment shows potential in graft-versus-host disease

MaaT Pharma, a clinical-stage biotech company developing microbiome ecosystem therapies, has presented positive results from a recent study investigating its lead product MaaT013 for patients with steroid-refractory (SR) or steroid-dependent (SD) gastrointestinal acute graft-versus-host Disease (GI-aGvHD). ....

United States , France General , Mohamad Mohty , Drug Administration , Sorbonne University , American Society Of Hematology , Annual Meeting , Saint Antoine Hospital , Microbiome Therapies , Bio Developments , Emerging Markets , Biotech Companies , Clinical Trials ,

MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023

MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France General , United States , Early Access Program , Senior Pr Corporate Communications , Professor Of Hematology At Sorbonne University , Trophic Communications , European Medicines Agency , American Society Of Hematology , Cellular Therapy Department At Saint Antoine Hospital , Drug Administration , Microbiome Ecosystem , Professor Mohty , Sorbonne University , Clinical Hematology , Cellular Therapy Department , Saint Antoine Hospital , Microbiome Therapies , Complete Response , Overall Response Rate , Maat Pharma , Microbiome Ecosystem Therapies , Euronext Paris , Orphan Drug Designation , Medicinal Products , Human Use , Early Access ,

Ferring Pharmaceuticals: Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021

Ferring Pharmaceuticals: Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021
Clostridioides difficile Infection With and Without Sepsis
Presenting Author: Alpesh Amin, MD, MBA, Thomas Mary Cesario Chairman, Department of Medicine, Executive Director, Hospitalist Program, University of California Irvine
EMBARGOED UNTIL PRESENTATION TIME: FRIDAY, MAY 21 AT 12:15 PM ET
DDW has made abstracts available on their website.
About RBX2660
RBX2660 is a potential first-in-class microbiota-based live biotherapeutic being studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent
C. difficile infection. RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). The pivotal Phase 3 program builds on nearly a decade of research with robust clinical and microbiome dat ....

United States , Heather Guzzi , Courtney Jones , Lindsey Rodger , Lee Jones , Thomas Mary Cesario , Kostenloser Wertpapierhandel , Colleen Kraft , Alpesh Amin , Christine Lee , Us Centers For Disease , American Society For Gastrointestinal Endoscopy , University Of California Irvine , Emory University School Of Medicine , Island Health , Communications Digital Innovation , Division Of Infectious Diseases , Ferring Company , Laboratory Medicine , Hospitalist Program , Rebiotix Inc , American Gastroenterological Association , Department Of Medicine , Centers For Disease , Brand Communications , Society For Surgery Of The Alimentary Tract ,